Massive Bio is a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial enrollment
Massive Bio’s mission is to provide access to clinical trials for every cancer patient regardless of his/her location and/or financial stability.
Massive Bio was founded in 2014 by Selin Kurnaz, Arturo Loaiza-Bonilla, and Cagatay M. Culcuoglu. The company is headquartered in New York, New York.
Massive Bio controls patient enrollment value chain starting patient identification, following with AI based virtual pre-screening outside the site and resolving last mile issues for clinical trial enrollment.
Massive Bio is the only company in the market that simultaneously provides patient identification, pre-screening, and concierge enrollment enablement while being focused on oncology and highly innovative data, technology, and services in a completely broken clinical trial enrollment value chain.
Massive Bio currently has 60,000 cancer patients and 26 pharma/CRO/provider systems customers. The company is consistently a market innovator with its 100K Singularity initiative, Oncology clinical trial command center, Amber Specialty partnership or being the vendor of choice of NCI.
Massive Bio is backed by International Private Bank (IPB), Revo Capital, Cavendish Impact Foundation (CIF), DEG, the German Development Finance Institution, and others. The company raised $9M in new round on Jun 02, 2022. This brings Massive Bio's total funding to $15.8M to date.